Results 111 to 120 of about 1,079,858 (266)

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with <i>PD-L1</i> amplification: a case report. [PDF]

Ther Adv Med Oncol
Kodama H, Masuishi T, Ishizuka Y, Sakakida T, Honda K, Narita Y, Taniguchi H, Kadowaki S, Ando M, Hosoda W, Muro K.   +10 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Pan-cancer 8q24 amplification predicts primary immunotherapy resistance and therapeutic vulnerabilities. [PDF]

iScience
Chen C, Liu S, Feng J, Luo Z, Bi Y, Huang Q, Zhang Y, Yu H, Wu J, Yu H, Liu R, Hu J, Ye L, Zhu Y, He Y, Chen L, Lu L, Gong K.   +17 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Correction: 89Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs

EJNMMI Research
Kevin Wyszatko, Melissa Chassé, Nancy Janzen, Luis Rafael Silva, Luke Kwon, Teesha Komal, Manuela Ventura, Chitra Venugopal, Sheila K. Singh, John F. Valliant, Saman Sadeghi   +10 more
doaj   +1 more source

Establishment of duplex multi-enzyme isothermal rapid amplification detection method for bovine astrovirus and norovirus. [PDF]

Front Vet Sci
Jiang L, Zhao Y, Zhang Q, Luo W, Zhou J, Yu B.   +5 more
europepmc   +1 more source

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, EarlyView.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source

Extrachromosomal DNA Amplification as a Prognostic Factor for Cancer. [PDF]

J Pers Med
Gajewski F, Pec J, Kleinrok J, Pająk W, Pacyna K, Tokarzewska A, Krawczyk P.   +6 more
europepmc   +1 more source